Satellos Bioscience Inc.

MSCL

CA80401L3083

Biotechnology & Medical Research

Delayed Toronto S.E. Other stock markets 02:29:18 2024-05-16 pm EDT			5-day change	1st Jan Change
0.465 ^CAD	-1.06%		+1.09%	+8.14%

May. 14	Satellos Bioscience Q1 Loss Widens Due To Higher Expenses; But Says "On track" to initiate Phase 1 First-in-human Clinical Trials Mid-2024	MT
Mar. 27	Satellos Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

ICo Therapeutics Inc. Announces the Resignation of Susan Koppy from the Board of Directors

April 29, 2021 at 10:48 pm EDT

iCo Therapeutics Inc. announced the resignation of Susan Koppy as President of the Company and from the Board of Directors, effective April 30, 2021.

Latest news about Satellos Bioscience Inc.

Satellos Bioscience Q1 Loss Widens Due To Higher Expenses; But Says "On track" to initiate Phase 1 First-in-human Clinical Trials Mid-2024	May. 14	MT
Satellos Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Satellos Bioscience Announces FY 2023 Results	Mar. 27	MT
Satellos Presented "Positive" Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference	Mar. 04	MT
Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference	Mar. 04	CI
Satellos Bioscience Inc. Brief: Says Will commence trading on the Toronto Stock Exchange as of the opening of trading tomorrow	Feb. 14	MT
Satellos Bioscience Inc. Announces Promising Preliminary Data in Facioscapulohumeral Muscular Dystrophy	Feb. 13	CI
Satellos Bioscience Inc. Brief: Shares Jumped 13.4% on Monday; Co Recently Received Conditional Approval to Graduate to the Toronto Stock Exchange	Jan. 23	MT
Satellos Bioscience Inc. Brief: Announced Earlier Tuesday Management Team Update; Alan K. Jacobs, Chief Medical Officer Has Left to Pursue Other Opportunities; Jordan Dubow Engaged As Chief Medical Advisor	Jan. 23	MT
Satellos Bioscience Inc. Announces Executive Changes	Jan. 23	CI
Satellos Receives Conditional Approval To Graduate To The Toronto Stock Exchange	Jan. 16	MT
Satellos Bioscience Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 22	CI
Satellos Bioscience Announces 2023 Q3 Financial Results and Operational Highlights	Nov. 22	MT
Satellos Bioscience Inc. Announces Executive Changes	Nov. 22	CI
Satellos Biosciences Provides Update on Duchenne Muscular Dystrophy Program	Nov. 14	MT
Satellos Bioscience Inc. Discloses Drug Target and Provides Development Update on Duchenne Muscular Dystrophy Program	Nov. 14	CI
Satellos Bioscience Names New CFO; Up 3.8%	23-09-05	MT
Satellos Bioscience Inc. Announces CFO Changes	23-09-05	CI
Satellos Bioscience Inc. Announces Appointment of Warren Whitehead as Head of Corporate Strategy	23-09-05	CI
Satellos Bioscience Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-27	CI
Satellos Bioscience Inc. Announces Appointment of Alan K. Jacobs as Chief Medical Officer	23-06-07	CI
Satellos Bioscience Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-30	CI
Satellos Bioscience Inc. announced that it has received CAD 44.545796 million in funding	23-05-24	CI
Satellos Bioscience Inc. announced that it expects to receive CAD 44.545796 million in funding	23-05-09	CI
Satellos Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI

Chart Satellos Bioscience Inc.

Duration

Period

More charts

Satellos Bioscience Inc. is a Canada-based a drug discovery and development company with a focus on muscle regeneration. The Company is focused on developing medicines to treat degenerative muscle conditions. Its MyoReGenX platform is specifically designed to recreate the specialized muscle stem cell niche in vitro. MyoReGenX platform enables to map pathways which modulate muscle repair and regeneration, identify, and confirm drug targets, and test drug candidates for their ability to restore muscle stem cell repair mechanisms that have been impaired by genetic mutations, disease or injury. Its lead program is an oral, small molecule drug candidate in development as a disease-modifying treatment for Duchenne muscular dystrophy. Its iCo portfolio includes Oral Amp B Delivery System, a patented oral transport technology and Bertilimumab a human monoclonal eotaxin antibody with potential to treat a range of allergic and inflammatory conditions mediated by eotaxin-1.

Sector

Biotechnology & Medical Research

Calendar

May. 14 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.47 CAD

Average target price

1.2 CAD

Spread / Average Target

+155.32%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SATELLOS BIOSCIENCE INC.	+8.14%	38.97M
VERTEX PHARMACEUTICALS INCORPORATED	+7.60%	113B
REGENERON PHARMACEUTICALS, INC.	+10.39%	106B
ARGENX SE	+0.41%	22.27B
BIONTECH SE	-11.89%	22.22B
GENMAB A/S	-5.99%	19.43B
WUXI APPTEC CO., LTD.	-37.36%	17.87B
BEIGENE, LTD.	-5.25%	17.24B
NEUROCRINE BIOSCIENCES, INC.	+6.57%	14.29B
SAREPTA THERAPEUTICS, INC.	+36.18%	12.52B

Bio Therapeutic Drugs

Satellos Bioscience Inc.

Equities

MSCL

CA80401L3083

Biotechnology & Medical Research

ICo Therapeutics Inc. Announces the Resignation of Susan Koppy from the Board of Directors

Latest news about Satellos Bioscience Inc.

Chart Satellos Bioscience Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs